TABLE 2.

Relationships between the viral load decline at weeks 2, 6, and 26 and the amprenavir, lopinavir, and ritonavir IQs (univariate analysis)

Drug	IQ typea	Week	No. of patients	Median (range)	P value at week:
					2	6	26
Amprenavir	IQsd	2	13	4.3 (0.62-25.9)	0.04	0.24	0.70
		6	13	1.8 (0.20-11.7)		0.80	0.26
	GIQ	2	14	81.2 (17.9-291.1)	0.0004	0.02	0.16
		6	14	26.4 (9.8-69.1)		0.56	0.59
Lopinavir	IQsd	2	21	4.0 (0.16-153.3)	0.97	0.65	0.66
		6	21	2.0 (0.15-157.5)		0.70	0.80
	GIQ	2	23	23.9 (6.6-177.6)	0.37	0.20	0.20
		6	23	17.8 (3.6-182.5)		0.15	0.36
Ritonavir	IQsd	2	34	0.01 (0.0004-0.5)	0.55	0.18	0.28
		6	34	0.005 (0.0004-0.8)		0.34	0.87
	GIQ	2	37	1.7 (0.12-19.1)	0.18	0.10	0.12
		6	37	1.3 (0.12-20.4)		0.16	0.45
Amprenavir + lopinavir	IQsd	6	34	4.9 (0.36-166.5)		0.34	0.71
	GIQ	6	37	46.9 (15.9-543.4)		0.03	0.15
Amprenavir + lopinavir + ritonavir	IQsd	6	34	4.9 (0.37-167.3)		0.34	0.71
	GIQ	6	37	48.8 (16.0-549.3)	0.03	0.15

^aStandard IQ (IQsd): (corrected C_min [calculated protein-unbound C_minu] at week 2 or 6)/IC₉₀ standard at week −2. GIQ: (corrected C_min [calculated protein-unbound C_minu] at week 2 or 6)/number of protease mutations at week −2.